Results 201 to 210 of about 108,133 (341)

Artificial lipidation of proteins and peptides: from mechanism to clinical applications

The FEBS Journal, EarlyView.
Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. [PDF]

PLoS Med
Chao AM, Gilden A, Wadden TA.
europepmc   +1 more source

The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition. [PDF]

Int J Mol Sci
Chrysavgis L, Mourelatou NG, Koloutsou ME, Rozani S, Cholongitas E.   +4 more
europepmc   +1 more source

Effect of switching from intermittently scanned continuous glucose monitoring to FreeStyle Libre 2 with real‐time continuous glucose monitoring and alert functionality

Journal of Diabetes Investigation, EarlyView.
Transitioning from FSL to FSL2 with rtCGM function improved sensor usage and glycemic control, particularly in patients with Type 1 diabetes. The duration required for improvement in continuous glucose monitoring‐related parameters varied by diabetes type, with early improvements observed in Type 1 diabetes and gradual improvements in Type 2 diabetes ...
Keiji Sugai, Junko Sasaki, Gakuyuki Tomizawa, Ryo Suzuki   +3 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework. [PDF]

Cancer Med
Dalbeni A, Vicardi M, Natola LA, Cattazzo F, Auriemma A, Lombardi R, Cinque F, Dalle Carbonare L, Mantovani A, Sacerdoti D.   +9 more
europepmc   +1 more source

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua   +7 more
wiley   +1 more source

Efficacy of probiotics (Bifidobacterium bifidum G9‐1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open‐label, single‐arm study (BIRDIE study)

Journal of Diabetes Investigation, EarlyView.
Bifidobacterium bifidum G9‐1 improved stool form, defecation frequency, and Quality of Life in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation. ABSTRACT Introduction Although constipation is a major complication of type 2 diabetes mellitus and chronic kidney disease, evidence for its treatment in these ...
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Masahiro Sugawara, Hiroaki Satoh, Yukiko Sugawara, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +10 more
wiley   +1 more source

Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This retrospective study compared oral semaglutide and SGLT2 inhibitors in patients with type 2 diabetes over 6 months. Both treatments significantly reduced HbA1c, body weight, and fat mass. Although the reduction in fat mass was comparable, changes in skeletal muscle mass tended to be less favorable with SGLT2 inhibitors than with oral semaglutide ...
Yasuhiro Omori, Ryota Usui, Yuji Yamazaki, Hitoshi Kuwata, Yoshiyuki Hamamoto, Yuichiro Yamada, Yutaka Seino   +6 more
wiley   +1 more source

The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials. [PDF]

Life (Basel)
Pilśniak J, Węgrzynek-Gallina J, Bednarczyk B, Buczek A, Pilśniak A, Chmiela T, Jarosińska A, Siuda J, Holecki M.   +8 more
europepmc   +1 more source

Endogenous GIP signaling is indispensable for DPP‐4 inhibitor‐mediated metabolic control in mice

Journal of Diabetes Investigation, EarlyView.
This study reveals that the metabolic benefits of DPP‐4 inhibitors, including improved glucose tolerance and reduced body weight, are completely abolished in GIP receptor‐deficient mice. These findings establish that endogenous GIP signaling, rather than GLP‐1, is the indispensable key player for the efficacy of this drug class.
Saki Kubota‐Okamoto, Sodai Kubota, Hiromi Tsuchida, Yanyan Liu, Seiya Banno, Toshinori Imaizumi, Taro Fujisawa, Yoshihiro Takahashi, Takehiro Kato, Yukio Horikawa, Katsumi Iizuka, Takaaki Murakami, Yuuka Fujiwara, Hitoshi Kuwata, Yuji Yamazaki, Yutaka Seino, Shin Tsunekawa, Daisuke Yabe   +17 more
wiley   +1 more source